IVIG Effectively Increased Platelet Counts in Maternal Thrombocytopenia
A recent study that sought to evaluate the efficacy of intravenous immune globulin (IVIG) and identify predictors of platelet response in pregnant persons with moderate-to-severe thrombocytopenia, as well as to optimize clinical decisions and resource use, has found that IVIG effectively increases platelet counts.
Nasal Spray Blocks Infuenza in Mice
Scientists at Ohio State University have created an antibody that was successful in protecting a majority of the tested mice from lethal influenza (flu) doses, even preventing some from experiencing any symptoms at all.
New Antibiotic Enters Phase III Trials to Fight Superburg
Roche’s novel antibiotic zosurabalpin is entering Phase III testing to determine its effectiveness in protecting against carbapenem-resistant Acinetobacter baumannii (CRAB), am antimicrobial resistance (AMR) drug, or “superbug,” that is considered an “urgent threat” by the Centers for Disease Control and Prevention (CDC).
FDA Approves Alzheimer’s Blood Test
The U.S. Food and Drug Administration has given marketing clearance to the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, a blood test to help diagnose Alzheimer’s disease for adults 55 and older who are showing signs and symptoms of the disease. It is the first test to be approved to aid in the early detection of the disease in the United States.
Novavax’s COVID-19 Vaccine Approved for Older Adults and At-Risk Individuals
After a six-week delay, the U.S. Food and Drug Administration approved Novavax’s COVID-19 vaccine, but only for people 65 and older and those 12 years and older who have at least one underlying condition, such as asthma, diabetes, lung disease, obesity and pregnancy, that puts them at higher risk of severe illness.
Combination Flu and COVID-19 Vaccine Prompts Immune Response in Older Adults
A recent study of Moderna’s combination influenze (flu) and COVID-18 vaccine, mRNA-1083, found that it induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all four influenza strains (among those ages 50 to 64 years), the three clinically relevant influenza strains (among those aged 65 years and older), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile.
Study Finds RSV Vaccines Protect Older Adults with 75 Percent Effectiveness
A comprehensive new study published in JAMA Network Open revealed that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged 60 and older, with approximately 75 percent effectiveness against RSV-associated respiratory illness. In the study, researchers analyzed data from more than 787,000 older adults tested for RSV between October 2023 and April 2024, […]
FDA Approves New FcRN Blocker to Treat Generalized Myasthenia Gravis
Johnson & Johnson has received U.S. Food and Drug Administration (FDA) approval for IMAAVY (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis
Uplizna Approved to Treat IgG4-Related Disease
Amgen’s UPLIZNA has been approved by the U.S. Food and Drug Administration as the first and only treatment for adults living with Immunoglobulin G4-related disease.
Grifols Receives $21M to Study Parkinson’s Plasma Samples
Grifols has received $21 million from the Michael J. Fox Foundation to fund a pilot study analyzing the company’s repository of longitudinal Parkinson’s disease (PD) plasma samples in hopes of developing an early-warning system for the emergence of PD.
